hVIVO PLC Presentation at World Vaccine Congress
March 29 2023 - 1:00AM
RNS Non-Regulatory
TIDMHVO
hVIVO PLC
29 March 2023
hVIVO plc
("hVIVO" or the "Company")
World Vaccine Congress Presentation
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc)
a rapidly growing specialist contract research organisation (CRO)
and world leader in testing infectious and respiratory disease
products using human challenge clinical trials, announces that Dr
Andrew Catchpole, Chief Scientific Officer, will be delivering a
presentation at the World Vaccine Congress, Washington D.C., United
States. Full details of the presentation are included below:
Title Challenge Studies - can the results be expected
to mimic field trial data?
Date/Time Wednesday 5 April 2023, 17.10 (ET)
The World Vaccine Congress will take place at the Walter E.
Washington Convention Center in Washington D.C. between 3-6 April
2023. hVIVO will be at booth 813 during the congress for potential
partnering discussions.
The World Vaccine Congress, organised by Terrapin, is the
largest and most established meeting dedicated to vaccines and has
run for 23 years. From basic research to commercial manufacture,
the event covers the whole vaccine value chain, with hundreds of
speakers and thousands of attendees from leading global vaccines
developers, academia and policymakers.
More information about the event, including attendance, can be
found here .
To request meetings with hVIVO at the World Vaccine Congress,
interested parties should register with Swapcard and use the
following link or by emailing bd@hvivo.com
Yamin 'Mo' Khan, Chief Executive Officer at hVIVO, said: "I am
delighted that Andrew will be presenting at the largest vaccine
event of the year amongst many other notable speakers, discussing
the significant value of human challenge trial data . As the global
leader in conducting human challenge trials to test vaccines and
antivirals for infectious and respiratory diseases, we are looking
forward to participating in roundtable discussions and sharing
insights into how human challenge trials can accelerate the drug
development process."
For further information please contact:
hVIVO plc +44 (0) 20 7756 1300
Yamin 'Mo' Khan, Chief Executive
Officer
Stephen Pinkerton, Chief Financial
Officer
Liberum Capital (Nominated Adviser and
Joint Broker) +44 (0) 20 3100 2000
Ben Cryer, Edward Mansfield, Phil Walker,
Will King
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash, Charlie Beeson, Nigel Birks,
Harriet Ward (ECM)
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) +44 (0) 20 7933 8780 or hvivo@walbrookpr.com
Stephanie Cuthbert / Phillip +44 (0) 7796 794 663 / +44 (0) 7867 984
Marriage / 082 /
Louis Ashe-Jepson +44 (0) 7747 515 393
Notes to Editors
About hVIVO
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly
growing specialist contract research organisation (CRO) and the
world leader in testing infectious and respiratory disease vaccines
and therapeutics using human challenge clinical trials. The Group
provides end-to-end early clinical development services to its
large, established and growing repeat client base, which includes
four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique
portfolio of 11 human challenge models, with a number of new models
under development, to test a broad range of infectious and
respiratory disease products. The Company has world class challenge
agent manufacturing, specialist drug development and clinical
consultancy services via its Venn Life Sciences brand, and a lab
offering via its hLAB brand, which includes virology, immunology
biomarker and molecular testing. The Group offers additional
clinical field trial services such as patient recruitment and
clinical trial site services.
hVIVO runs challenge studies in London from its Whitechapel
quarantine clinic, its state-of-the-art QMB clinic with its highly
specialised on-site virology and immunology laboratory, and its
clinic in Plumbers Row. To recruit volunteers / patients for its
studies, the Company leverages its unique clinical trial
recruitment capacity via its FluCamp volunteer screening facilities
in London and Manchester.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGZGZFKRRGFZM
(END) Dow Jones Newswires
March 29, 2023 02:00 ET (06:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Dec 2023 to Dec 2024
